The productivity crisis in pharmaceutical R&D

Citation Report

#	Article	IF	Citations
1	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 442.	0.6	122
2	The development of label-free cellular assays for drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 1285-1298.	2.5	54
3	Targeting Protein–Protein Interactions and Fragment-Based Drug Discovery. Topics in Current Chemistry, 2011, 317, 145-179.	4.0	88
4	Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opinion on Biological Therapy, 2011, 11, 1469-1484.	1.4	433
5	How to Revive Breakthrough Innovation in the Pharmaceutical Industry. Science Translational Medicine, 2011, 3, 89cm16.	5.8	85
6	Have animal models of disease helped or hindered the drug discovery process?. Annals of the New York Academy of Sciences, 2011, 1245, 1-2.	1.8	14
7	The influence of the 'organizational factor' on compound quality in drug discovery. Nature Reviews Drug Discovery, 2011, 10, 749-765.	21.5	146
8	State of the art technologies in drug discovery 2011. Current Opinion in Chemical Biology, 2011, 15, 461-462.	2.8	0
9	Markets for Pharmaceutical Products11The authors thank Tom McGuire for editorial advice and improvements and participants at the Handbook conference for helpful suggestions.. Handbook of Health Economics, 2011, 2, 763-823.	0.2	22
10	Business models and opportunities for cancer vaccine developers. Human Vaccines and Immunotherapeutics, 2012, 8, 1431-1438.	1.4	4
11	Personalized Cardiovascular Medicine and Drug Development. Circulation, 2012, 125, 638-645.	1.6	41
12	Deployment of in silico and in vitro safety assays in early-stage drug discovery. Future Medicinal Chemistry, 2012, 4, 1211-1213.	1.1	5
13	Improving success of novel therapeutics for cognitive aspects of psychiatric disease: a bridge too far?. Expert Review of Clinical Pharmacology, 2012, 5, 601-603.	1.3	0
14	Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics. Expert Opinion on Drug Discovery, 2012, 7, 1071-1082.	2.5	15
15	Novel Stem Cell–Based Drug Discovery Platforms for Cardiovascular Disease. Journal of Biomolecular Screening, 2012, 17, 1117-1127.	2.6	5
16	Connecting the dots in translational research. Nature Reviews Drug Discovery, 2012, 11, 811-812.	21.5	1
17	Translational Research and the Evolving Landscape for Biomedical Innovation. Journal of Investigative Medicine, 2012, 60, 995-998.	0.7	16
18	The Right Medicines—Just Not Enough of Them. Clinical Pharmacology and Therapeutics, 2012, 91, 369-372.	2.3	1

#	ARTICLE	IF	CITATIONS
19	The art of the alliance. Bioentrepreneur, 2012, , .	0.2	0
20	Healthcare payers: a gate or translational bridge to personalized medicine?. Personalized Medicine, 2012, 9, 73-84.	0.8	5
21	An Integrated Drug Development Approach Applying Topological Descriptors. Current Computer-Aided Drug Design, 2012, 8, 172-181.	0.8	40
23	Human Mendelian pain disorders: a key to discovery and validation of novel analgesics. Clinical Genetics, 2012, 82, 367-373.	1.0	34
24	Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Research and Treatment, 2012, 136, 179-185.	1.1	28
25	Recycling side-effects into clinical markers for drug repositioning. Genome Medicine, 2012, 4, 3.	3.6	39
26	Addressing the Medicinal Chemistry Bottleneck: A Lean Approach to Centralized Purification. ACS Combinatorial Science, 2012, 14, 520-526.	3.8	12
27	Open innovation: the new face of pharmaceutical research and development. Expert Review of Clinical Pharmacology, 2012, 5, 481-483.	1.3	19
28	Probing Biochemical Mechanisms of Action of Muscarinic M3 Receptor Antagonists with Label-Free Whole Cell Assays. Analytical Chemistry, 2012, 84, 8232-8239.	3.2	38
29	The Valley of Death in anticancer drug development: a reassessment. Trends in Pharmacological Sciences, 2012, 33, 173-180.	4.0	80
30	Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 2012, 11, 191-200.	21.5	1,520
31	System-based drug discovery within the human kinome. Expert Opinion on Drug Discovery, 2012, 7, 1053-1070.	2.5	32
32	Metabolic Disease Drug Discoveryâ€" â€œHitting the Targetâ€•Is Easier Said Than Done. Cell Metabolism, 2012, 15, 19-24.	7.2	35
33	The art of the alliance. Nature Biotechnology, 2012, 30, 313-315.	9.4	3
34	Simulating the drug discovery pipeline: a Monte Carlo approach. Journal of Cheminformatics, 2012, 4, 32.	2.8	7
35	Exploring Aromatic Chemical Space with NEAT: Novel and Electronically Equivalent Aromatic Template. Journal of Chemical Information and Modeling, 2012, 52, 1114-1123.	2.5	16
36	Ligandâ€"receptor interaction platforms and their applications for drug discovery. Expert Opinion on Drug Discovery, 2012, 7, 969-988.	2.5	97
37	Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy. Journal of Chemical Information and Modeling, 2012, 52, 2937-2949.	2.5	36

#	Article	IF	Citations
39	The virtuous technology cycle concept and its application in next-generation sequencing. Drug Discovery Today, 2012, 17, 1015-1022.	3.2	0
40	Translational CNS medicines research. Drug Discovery Today, 2012, 17, 1068-1078.	3.2	47
41	Analysing stratified medicine business models and value systems: innovation-regulation interactions. New Biotechnology, 2012, 29, 709-719.	2.4	21
42	Comparison of the quantification of a therapeutic protein using nominal and accurate mass MS/MS. Bioanalysis, 2012, 4, 605-615.	0.6	34
43	The Emerging Paradigm of Network Medicine in the Study of Human Disease. Circulation Research, 2012, 111, 359-374.	2.0	186
44	Chemical Optimization of New Ligands of the Low-Density Lipoprotein Receptor as Potential Vectors for Central Nervous System Targeting. Journal of Medicinal Chemistry, 2012, 55, 2227-2241.	2.9	71
45	Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of â€œSecondaryâ€•Pharmaceutical Patents. PLoS ONE, 2012, 7, e49470.	1.1	83
46	Big Pharma, Little Science? A Bibliometric Perspective on Big Pharmaâ€™s R&D Decline. SSRN Electronic Journal, 2012, , .	0.4	5
47	Where will the (New) Drugs for Traumatic Brain Injury Treatment be Coming From?. Frontiers in Neurology, 2012, 3, 27.	1.1	7
48	Perspectives on the Discovery of Small-Molecule Modulators for Epigenetic Processes. Journal of Biomolecular Screening, 2012, 17, 555-571.	2.6	21
49	Bioinformatics and variability in drug response: a protein structural perspective. Journal of the Royal Society Interface, 2012, 9, 1409-1437.	1.5	66
50	The developability of heteroaromatic and heteroaliphatic rings â€" do some have a better pedigree as potential drug molecules than others?. MedChemComm, 2012, 3, 1062.	3.5	144
51	Biosynthetic medicinal chemistry of natural product drugs. MedChemComm, 2012, 3, 854.	3.5	37
52	Evaluation of Competing Process Concepts for the Production of Pure Enantiomers. Organic Process Research and Development, 2012, 16, 353-363.	1.3	47
53	Learning from Failures or Failing to Learn? Lessons from Pharmaceutical R&D. European Management Review, 2012, 9, 45-58.	2.2	38
54	Translational semantics and infrastructure: another search for the emperor's new clothes?. Drug Discovery Today, 2012, 17, 459-468.	3.2	29
55	Collaborative approaches to anticancer drug discovery and development: a Cancer Research UK perspective. Drug Discovery Today, 2012, 17, 185-187.	3.2	15
56	Advance Market Commitments for <scp>R</scp>&<scp>D</scp> in Diseases That Disproportionately Affect Lowâ€‐Income Countries. Journal of World Intellectual Property, 2012, 15, 280-303.	0.2	1

#	ARTICLE	IF	CITATIONS
57	NIPTE: a multi-university partnership supporting academic drug development. Drug Discovery Today, 2013, 18, 916-921.	3.2	7
58	Challenges for PEGylated Proteins and Alternative Half-Life Extension Technologies Based on Biodegradable Polymers. ACS Symposium Series, 2013, , 215-233.	0.5	14
59	A new approach to assess drug development performance. Drug Discovery Today, 2013, 18, 420-427.	3.2	8
60	Unbinding Pathways from the Glucocorticoid Receptor Shed Light on the Reduced Sensitivity of Glucocorticoid Ligands to a Naturally Occurring, Clinically Relevant Mutant Receptor. Journal of Medicinal Chemistry, 2013, 56, 7003-7014.	2.9	29
61	Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis. BMC Bioinformatics, 2013, 14, 221.	1.2	58
62	Bibliometrics evaluation of research performance in pharmacology/pharmacy: China relative to ten representative countries. Scientometrics, 2013, 96, 829-844.	1.6	29
63	The new pig on the block: modelling cancer in pigs. Transgenic Research, 2013, 22, 673-680.	1.3	50
64	Discontinued drugs in 2012: cardiovascular drugs. Expert Opinion on Investigational Drugs, 2013, 22, 1437-1451.	1.9	5
65	High-Throughput Screening in Traditional Chinese Medicine-Based Drug Discovery. , 2013, , 387-404.		0
66	The New Geography of Innovation. , 2013, , .		4
68	The political economy of healthcare reform in China: negotiating public and private. SpringerPlus, 2013, 2, 448.	1.2	42
69	Drugs by Numbers: Reaction€Driven De Novo Design of Potent and Selective Anticancer Leads. Angewandte Chemie - International Edition, 2013, 52, 4676-4681.	7.2	22
70	Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980-2009. Industrial and Corporate Change, 2013, 22, 903-952.	1.7	27
71	How can attrition rates be reduced in cancer drug discovery?. Expert Opinion on Drug Discovery, 2013, 8, 363-368.	2.5	97
72	Novel Antiplatelet Therapies. , 2013, , 1185-1213.		4
73	Objective assessment of cancer genes for drug discovery. Nature Reviews Drug Discovery, 2013, 12, 35-50.	21.5	111
74	Discontinued drugs in 2011: oncology drugs. Expert Opinion on Investigational Drugs, 2013, 22, 9-34.	1.9	18
75	Mechanistic systems modeling to guide drug discovery and development. Drug Discovery Today, 2013, 18, 116-127.	3.2	47

#	ARTICLE	IF	CITATIONS
76	The application of Chinese medicine to novel drug discovery. Expert Opinion on Drug Discovery, 2013, 8, 21-34.	2.5	89
78	Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems. Health Policy, 2013, 113, 305-312.	1.4	31
79	Targeting melanoma by small molecules: challenges ahead. Pigment Cell and Melanoma Research, 2013, 26, 464-469.	1.5	10
80	Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery. Journal of Pharmacological and Toxicological Methods, 2013, 67, 69-81.	0.3	35
82	De novo design and optimization of Aurora A kinase inhibitors. Chemical Science, 2013, 4, 1229.	3.7	23
83	Design principles for innovative workspaces to increase efficiency in pharmaceutical R&D: lessons learned from the Novartis campus. Drug Discovery Today, 2013, 18, 318-322.	3.2	11
84	Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file. Molecular Diversity, 2013, 17, 319-335.	2.1	7
85	Translational research: the changing landscape of drug discovery. Drug Discovery Today, 2013, 18, 487-494.	3.2	39
86	The most transformative drugs of the past 25 years: a survey of physicians. Nature Reviews Drug Discovery, 2013, 12, 425-431.	21.5	39
87	â€œCollaborative Innovationâ€â€"Regaining the Edge in Drug Discovery. Angewandte Chemie - International Edition, 2013, 52, 2684-2687.	7.2	7
88	Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discovery Today, 2013, 18, 211-217.	3.2	93
89	â€˜Smartâ€™ non-viral delivery systems for targeted delivery of RNAi to the lungs. Therapeutic Delivery, 2013, 4, 59-76.	1.2	12
90	Structural Systems Pharmacology: The Role of 3D Structures in Next-Generation Drug Development. Chemistry and Biology, 2013, 20, 674-684.	6.2	42
91	Reducing Drug Attrition: Safety Pharmacology. Topics in Medicinal Chemistry, 2013, , 139-158.	0.4	0
92	Chemical Biology Consortium Sweden. ACS Chemical Biology, 2013, 8, 2605-2606.	1.6	7
93	Pressure-Driven Microfluidic Perfusion Culture Device for Integrated Dose-Response Assays. Journal of the Association for Laboratory Automation, 2013, 18, 437-445.	2.8	6
95	Championing cardiovascular health innovation in Europe. European Heart Journal, 2013, 34, 2630-2635.	1.0	8
96	Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways. PLoS Computational Biology, 2013, 9, e1003226.	1.5	84

#	ARTICLE	IF	CITATIONS
97	Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals. Clinical Cancer Research, 2013, 19, 3722-3731.	3.2	26
98	Investigation of Characteristics of Japanese Clinical Trials in Terms of Data Variability. Therapeutic Innovation and Regulatory Science, 2013, 47, 430-437.	0.8	2
99	Legal and Political Competitiveness for Pharmaceuticals. Pharmaceuticals Policy and Law, 2013, 15, 93-97.	0.1	1
100	Transforming pain medicine: Adapting to science and society. European Journal of Pain, 2013, 17, 1109-1125.	1.4	45
101	Chemically Advanced Template Search (CATS) for Scaffold‐Hopping and Prospective Target Prediction for â€˜Orphanâ€™ Molecules. Molecular Informatics, 2013, 32, 133-138.	1.4	132
102	Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the <scp>P</scp>redictive <scp>S</scp>afety <scp>T</scp>esting <scp>C</scp>onsortium. Drug Development Research, 2013, 74, 112-126.	1.4	11
103	Importance and hurdles to drug discovery for neurological disease. Annals of Neurology, 2013, 74, 441-446.	2.8	15
105	Developability assessment as an early de-risking tool for biopharmaceutical development. Pharmaceutical Bioprocessing, 2013, 1, 29-50.	0.8	51
106	Â¿QuÃ© aportan los nuevos fÃ¡rmacos antiepilÃ©pticos?. Revista MÃ©dica ClÃnica Las Condes, 2013, 24, 995-1003.	0.2	0
110	The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-4.	1.3	53
111	The Dynamics of Pharmaceutical Regulation and R&D Investments. SSRN Electronic Journal, 2013, , .	0.4	1
112	Drugs for solid cancer the productivity crisis prompts a rethink. OncoTargets and Therapy, 2013, 6, 767.	1.0	9
113	Championing cardiovascular health innovation in Europe. Acta Cardiologica, 2013, 68, 650-655.	0.3	1
114	Stock Market Returns and Clinical Trial Results of Investigational Compounds: An Event Study Analysis of Large Biopharmaceutical Companies. PLoS ONE, 2013, 8, e71966.	1.1	23
115	Drug discovery and development. , 2013, , 321-334.		1
116	Label-free drug discovery. Frontiers in Pharmacology, 2014, 5, 52.	1.6	66
117	From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action. Frontiers in Cell and Developmental Biology, 2014, 2, 37.	1.8	20
118	Mergers and Alliances in the Biopharmaceuticals Industry. , 2014, , 279-291.		2

#	Article	IF	Citations
119	R&D Implementation in a Department of Laboratory Medicine and Pathology: A Systematic Review Based on Pharmaceutical Companies. Global Journal of Health Science, 2014, 7, 70-82.	0.1	3
120	Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays. Oncotarget, 2014, 5, 659-666.	0.8	5
122	A high efficiency, high quality and low cost internal regulated bioanalytical laboratory to support drug development needs. Bioanalysis, 2014, 6, 1295-1309.	0.6	4
123	Molecular biomarkers in clinical development: what could we learn from the clinical trial registry?. Personalized Medicine, 2014, 11, 381-393.	0.8	2
124	Pharmaceutical regulation in Europe and its impact on corporate R&D. Health Economics Review, 2014, 4, 23.	0.8	23
125	Regenerative Medicine: Transforming the Drug Discovery and Development Paradigm. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a014084-a014084.	2.9	9
126	Towards personalized agriculture: what chemical genomics can bring to plant biotechnology. Frontiers in Plant Science, 2014, 5, 344.	1.7	9
127	Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development. Frontiers in Pharmacology, 2014, 5, 247.	1.6	57
128	Knowledge-based Fragment Binding Prediction. PLoS Computational Biology, 2014, 10, e1003589.	1.5	32
129	Translation Strategy for the Qualification of Drug-induced Vascular Injury Biomarkers. Toxicologic Pathology, 2014, 42, 658-671.	0.9	13
130	Production of Drug-Loaded Polymeric Nanoparticles by Electrospraying Technology. Journal of Biomedical Nanotechnology, 2014, 10, 2200-2217.	0.5	34
131	The ethical dimension in published animal research in critical care: the public face of science. Critical Care, 2014, 18, R15.	2.5	30
132	How can we discover safer drugs?. Future Medicinal Chemistry, 2014, 6, 481-483.	1.1	12
133	The biggest challenges currently facing companion diagnostic advancement. Expert Review of Molecular Diagnostics, 2014, 14, 27-35.	1.5	5
134	Potential strategies for increasing drug-discovery productivity. Future Medicinal Chemistry, 2014, 6, 515-527.	1.1	18
135	Semantic Breakthrough in Drug Discovery. Synthesis Lectures on the Semantic Web: Theory and Technology, 2014, 4, 1-142.	5.0	4
136	A chemo-centric view of human health and disease. Nature Communications, 2014, 5, 5676.	5.8	23
137	Drug Discovery Alliances in India-Indications, Targets, and New Chemical Entities. ChemMedChem, 2014, 9, 43-60.	1.6	5

#	Article	IF	Citations
138	Corporate venture capital and Cambridge. Nature Biotechnology, 2014, 32, 975-978.	9.4	3
139	Research and development productivity map: visualization of industry status. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 175-180.	0.7	14
140	Chapter 8. Utility of Human Stem Cells for Drug Discovery. RSC Drug Discovery Series, 2014, , 162-193.	0.2	2
141	Strategy of Daiichi Sankyo Discovery Research in Oncology. Japanese Journal of Clinical Oncology, 2014, 44, 109-115.	0.6	2
142	The effect size, study design, and development experience in commercially sponsored studies for new drug applications in approved drugs. SpringerPlus, 2014, 3, 740.	1.2	8
143	Advances in the treatment of aortic valve disease. Current Opinion in Pediatrics, 2014, 26, 546-552.	1.0	5
144	Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs. International Journal of Biological Sciences, 2014, 10, 654-663.	2.6	293
145	A lesson from Japan: Research and development efficiency is a key element of pharmaceutical industry consolidation process. Drug Discoveries and Therapeutics, 2014, 8, 57-63.	0.6	8
146	Targeted Chemotherapy, the Medical Ecosystem, and the Future of American Health Care. Perspectives in Biology and Medicine, 2014, 57, 268-284.	0.3	1
147	Science in Two Minds: Reflections on the Missional Disunity Within Contemporary Medicine. Christian Bioethics, 2014, 20, 359-375.	0.1	1
148	Synthetic Biology: Solving the Pharmaceutical Industry's Innovation Problems?. , 2014, , 11-18.		2
149	Induced pluripotent stem cells as cardiac arrhythmic *in vitro* models and the impact for drug discovery. Expert Opinion on Drug Discovery, 2014, 9, 55-76.	2.5	10
150	Big Pharma, little science?. Technological Forecasting and Social Change, 2014, 81, 22-38.	6.2	105
151	The fall and rise of pharmacology – (Re-)defining the discipline?. Biochemical Pharmacology, 2014, 87, 4-24.	2.0	28
152	Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discovery Today, 2014, 19, 171-182.	3.2	140
153	Animal models of human disease: Challenges in enabling translation. Biochemical Pharmacology, 2014, 87, 162-171.	2.0	396
154	The unmet need for philanthropic funding of early career cardiovascular investigators. Journal of Thrombosis and Thrombolysis, 2014, 37, 527-531.	1.0	2
155	Towards a sustainable system of drug development. Drug Discovery Today, 2014, 19, 1711-1720.	3.2	37

#	ARTICLE	IF	CITATIONS
156	Human stem cell-derived hepatocytes: breakthrough of an expedient tool for preclinical assessment of drug-induced liver injury?. Archives of Toxicology, 2014, 88, 183-184.	1.9	4
157	Reducing attrition in drug development: smart loading preclinical safety assessment. Drug Discovery Today, 2014, 19, 341-347.	3.2	74
158	Precompetitive Collaboration on Enabling Technologies for the Pharmaceutical Industry. Organic Process Research and Development, 2014, 18, 481-487.	1.3	21
159	Effects of Trade Related Intellectual Property Rights on the research and development expenditure of Indian pharmaceutical industry. Journal of Pharmaceutical Health Services Research, 2014, 5, 89-94.	0.3	1
160	Systems biology in drug discovery and development. Drug Discovery Today, 2014, 19, 113-125.	3.2	80
162	Do intangible assets explain high U.S. foreign direct investment returns?. Journal of Macroeconomics, 2014, 40, 159-171.	0.7	3
163	Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nature Reviews Drug Discovery, 2014, 13, 419-431.	21.5	1,067
164	Biological networks 101: Computational modeling for molecular biologists. Gene, 2014, 533, 379-384.	1.0	21
165	Systems biology, complexity, and the impact on antiepileptic drug discovery. Epilepsy and Behavior, 2014, 38, 131-142.	0.9	34
166	Substituted 2-Phenylimidazopyridines: A New Class of Drug Leads for Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2014, 57, 828-835.	2.9	67
167	Translational paradigms in pharmacology and drug discovery. Biochemical Pharmacology, 2014, 87, 189-210.	2.0	31
168	Biomolecular Display Technology. , 2014, , 369-384.		3
169	Replicated, replicable and relevantâ€"target engagement and pharmacological experimentation in the 21st century. Biochemical Pharmacology, 2014, 87, 64-77.	2.0	28
170	RISING R&D INTENSITY AND ECONOMIC GROWTH. Economic Inquiry, 2014, 52, 1427-1445.	1.0	2
171	Toxins and drug discovery. Toxicon, 2014, 92, 193-200.	0.8	156
172	Integrated Partnerships and the Transformation of Pharmaceutical Research and Development. Clinical Therapeutics, 2014, 36, 1346-1348.	1.1	4
173	The Paradox of Scientific Excellence and the Search for Productivity in Pharmaceutical Research and Development. Clinical Pharmacology and Therapeutics, 2014, 95, 521-527.	2.3	16
174	Academic drug discovery centres: the economic and organisational sustainability of an emerging model. Drug Discovery Today, 2014, 19, 1699-1710.	3.2	21

#	Article	IF	Citations
175	Human Skin-Derived Stem Cells as a Novel Cell Source for In Vitro Hepatotoxicity Screening of Pharmaceuticals. Stem Cells and Development, 2014, 23, 44-55.	1.1	48
176	Environmental side effects of pharmaceutical cocktails: What we know and what we should know. Journal of Hazardous Materials, 2014, 279, 169-189.	6.5	226
177	Naturally occurring scaffolds for compound library design: convenient access to bis-aryl 1-azaadamantanes carrying a vicinal amino alcohol motif. Tetrahedron Letters, 2014, 55, 5390-5393.	0.7	5
178	Target Selection and Validation in Drug Discovery. Topics in Medicinal Chemistry, 2014, , 1-72.	0.4	0
179	The methodological quality of animal research in critical care: the public face of science. Annals of Intensive Care, 2014, 4, 26.	2.2	28
180	The discovery of first-in-class drugs: origins and evolution. Nature Reviews Drug Discovery, 2014, 13, 577-587.	21.5	412
183	Design of Tunable Multicomponent Polymers as Modular Vehicles To Solubilize Highly Lipophilic Drugs. Macromolecules, 2014, 47, 6554-6565.	2.2	33
184	Consideration of the cellular microenvironment: Physiologically relevant co-culture systems in drug discovery. Advanced Drug Delivery Reviews, 2014, 69-70, 190-204.	6.6	43
185	Pricing schemes for new drugs: A welfare analysis. Social Science and Medicine, 2014, 102, 69-73.	1.8	24
186	Challenges Facing Early Career Academic Cardiologists. Journal of the American College of Cardiology, 2014, 63, 2199-2208.	1.2	51
187	Preparative two-dimensional liquid chromatography/mass spectrometry for the purification of complex pharmaceutical samples. Journal of Chromatography A, 2014, 1324, 86-95.	1.8	36
188	Restructuring and innovation in pharmaceuticals and biotechs: The impact of financialisation. Critical Perspectives on Accounting, 2014, 25, 67-77.	2.7	30
189	Biosynthonics: Charting the Future Role of Biocatalysis and Metabolic Engineering in Drug Discovery. Industrial & Engineering Chemistry Research, 2014, 53, 18597-18610.	1.8	3
190	Modulators of Protein–Protein Interactions. Chemical Reviews, 2014, 114, 4695-4748.	23.0	407
191	Reverse docking: a powerful tool for drug repositioning and drug rescue. Future Medicinal Chemistry, 2014, 6, 333-342.	1.1	106
192	The development speed paradox: can increasing development speed reduce R&D productivity?. Drug Discovery Today, 2014, 19, 209-214.	3.2	8
194	Corporate venture capital and Cambridge. Bioentrepreneur, 2014, , .	0.2	0
198	A focus on translational medicine is necessary to close the innovation gap in pharmaceutical medicine. Clinical Investigation, 2014, 4, 675-677.	0.0	0

#	Article	IF	Citations
199	Seamless Integration of Dose–Response Screening and Flow Chemistry: Efficient Generation of Structure–Activity Relationship Data of β–Secretase (BACE1) Inhibitors. Angewandte Chemie - International Edition, 2014, 53, 1704-1708.	7.2	45
206	Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study. BMJ Open, 2015, 5, e009333-e009333.	0.8	10
207	On valuing biopharmaceutical product pipelines: an effectuation model and evidence. Journal of Innovation and Entrepreneurship, 2015, 4, .	1.8	5
208	Professional translational research: a new hybrid paradigm in early drug discovery. Future Medicinal Chemistry, 2015, 7, 1879-1889.	1.1	3
209	Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics. Annals of the New York Academy of Sciences, 2015, 1346, 63-70.	1.8	8
211	Optimization Ophthalmic Topical Antifungal Treatment. Fungal Genomics & Biology, 2015, 05, .	0.4	1
212	Explicit Drug Re-positioning. Advances in Protein Chemistry and Structural Biology, 2015, 100, 89-112.	1.0	4
213	Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics. Frontiers in Pharmacology, 2015, 6, 179.	1.6	8
214	Reverse Innovation and Reverse Technology Transfer: From Made in China to Discovered in China in the Pharmaceutical Sector. Management International, 2015, 19, 49-69.	0.1	10
215	R&D Productivity in the Pharmaceutical Industry. International Journal of Strategic Decision Sciences, 2015, 6, 1-16.	0.0	4
219	Nanoscale monitoring of drug actions on cell membrane using atomic force microscopy. Acta Pharmacologica Sinica, 2015, 36, 769-782.	2.8	46
220	Expectations for methodology and translation of animal research: a survey of health care workers. BMC Medical Ethics, 2015, 16, 29.	1.0	2
221	The Life Sciences Translational Challenge: The European Perspective. Therapeutic Innovation and Regulatory Science, 2015, 49, 415-424.	0.8	2
222	What makes more, better? An exploratory study on the effects of firm-level commercial operations attributes on pharmaceutical business performance. Journal of Medical Marketing, 2015, 15, 10-25.	0.2	0
223	Behavioral studies on anxiety and depression in a drug discovery environment: Keys to a successful future. European Journal of Pharmacology, 2015, 753, 158-176.	1.7	17
224	Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease. Neurotherapeutics, 2015, 12, 132-142.	2.1	58
225	Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. European Neuropsychopharmacology, 2015, 25, 599-656.	0.3	113
226	A lung-on-a-chip array with an integrated bio-inspired respiration mechanism. Lab on A Chip, 2015, 15, 1302-1310.	3.1	296

#	ARTICLE	IF	CITATIONS
227	Surviving the gauntlet: Modern challenges in cardiovascular drug approval and implementation. American Heart Journal, 2015, 169, 191-193.	1.2	0
228	In search of novel anti-inflammatory agents: Computational repositioning of approved drugs. Journal of Computational Science, 2015, 10, 217-224.	1.5	6
229	Addressing the Right Targets in Oncology. Journal of Biomolecular Screening, 2015, 20, 305-317.	2.6	14
230	Maximizing computational tools for successful drug discovery. Expert Opinion on Drug Discovery, 2015, 10, 321-329.	2.5	52
231	Propeller-shaped molecules with a thiazole hub: structural landscape and hydrazone cap mediated tunable host behavior in 4-hydrazino-1,3-thiazoles. CrystEngComm, 2015, 17, 5978-5986.	1.3	3
232	Molecular mechanism matters: Benefits of mechanistic computational models for drug development. Pharmacological Research, 2015, 99, 149-154.	3.1	30
233	Discover a Drug Substance, Formulate, and Develop It to a Product. , 2015, , 793-803.		0
234	Top 100 bestselling drugs represent an arena struggling for new FDA approvals: drug age as an efficiency indicator. Drug Discovery Today, 2015, 20, 1300-1304.	3.2	6
235	Cardiovascular Drug Development. Journal of the American College of Cardiology, 2015, 65, 1567-1582.	1.2	168
236	An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Science Translational Medicine, 2015, 7, 284ra57.	5.8	150
237	Big Data in Pharmaceutical R&D: Creating a Sustainable R&D Engine. Pharmaceutical Medicine, 2015, 29, 87-92.	1.0	21
238	Systems biology approaches for advancing the discovery of effective drug combinations. Journal of Cheminformatics, 2015, 7, 7.	2.8	109
239	Protein localization vector propagation: a method for improving the accuracy of drug repositioning. Molecular BioSystems, 2015, 11, 2096-2102.	2.9	47
240	A new application of value-stream mapping in new drug development: a case study within Novartis. Drug Discovery Today, 2015, 20, 301-305.	3.2	7
241	<i>In silico</i> tools used for compound selection during target-based drug discovery and development. Expert Opinion on Drug Discovery, 2015, 10, 901-923.	2.5	16
242	The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs. Health Affairs, 2015, 34, 286-293.	2.5	73
243	Cheaper faster drug development validated by the repositioning of drugs against neglected tropical diseases. Journal of the Royal Society Interface, 2015, 12, 20141289.	1.5	97
244	Lead optimization attrition analysis (LOAA): a novel and general methodology for medicinal chemistry. Drug Discovery Today, 2015, 20, 978-987.	3.2	15

#	ARTICLE	IF	CITATIONS
245	Translational Medicine. , 2015, , 313-325.		3
246	The Pharmaceutical R&D Productivity Crisis. , 2015, , 227-228.		1
247	Target-based molecular modeling strategies for schistosomiasis drug discovery. Future Medicinal Chemistry, 2015, 7, 753-764.	1.1	27
248	An overview of peptide and peptoid foldamers in medicinal chemistry. Expert Opinion on Drug Discovery, 2015, 10, 1163-1177.	2.5	61
249	Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective. Drug Discovery Today, 2015, 20, 1310-1316.	3.2	86
250	Network Pharmacology for Traditional Chinese Medicine Research: Methodologies and Applications. Chinese Herbal Medicines, 2015, 7, 18-26.	1.2	23
251	A combined systems and structural modeling approach repositions antibiotics for Mycoplasma genitalium. Computational Biology and Chemistry, 2015, 59, 91-97.	1.1	13
252	Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens. ACS Infectious Diseases, 2015, 1, 401-402.	1.8	12
253	Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats. Journal of Nuclear Medicine, 2015, 56, 1793-1799.	2.8	10
254	Peering into the pharmaceutical â€œpipelineâ€: Investigational drugs, clinical trials, and industry priorities. Social Science and Medicine, 2015, 131, 322-330.	1.8	51
255	A decade of innovation in pharmaceutical R&D: the Chorus model. Nature Reviews Drug Discovery, 2015, 14, 17-28.	21.5	60
256	Hirsutenone in <i>Alnus</i> extract inhibits akt activity and suppresses prostate cancer cell proliferation. Molecular Carcinogenesis, 2015, 54, 1354-1362.	1.3	9
257	R&D productivity rides again?. Pharmaceutical Statistics, 2015, 14, 1-3.	0.7	20
258	A multiple regression model-based chemical biology approach to dissect signal transduction pathways downstream of cytokine receptors. International Journal of Computational Biology and Drug Design, 2016, 9, 277.	0.3	0
259	Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics. Oncotarget, 2016, 7, 40348-40361.	0.8	28
260	Current use of Antifungal Eye Drops and How to Improve Therapeutic Aspects in Keratomycosis. Fungal Genomics & Biology, 2016, 6, .	0.4	1
261	Quantitative Structureâ€"Activity Relationships. , 2016, , 163-192.		7
262	Business Models to Cure Rare Disease: A Case Study of Solid Biosciences. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
263	Returns to Society from Investment in Cancer Research and Development. Forum for Health Economics and Policy, 2016, 19, 71-86.	0.2	4
264	Prediscovery Research: Challenges and Opportunities. , 2016, , 85-108.		0
265	Microfabricated Physiological Models for In Vitro Drug Screening Applications. Micromachines, 2016, 7, 233.	1.4	19
266	Expectations for the Methodology and Translation of Animal Research: A Survey of the General Public, Medical Students and Animal Researchers in North America. ATLA Alternatives To Laboratory Animals, 2016, 44, 361-381.	0.7	6
267	Real Options and Incremental Search in Pharmaceutical <scp>R</scp>&<scp>D</scp> Project Portfolio Management. Creativity and Innovation Management, 2016, 25, 292-302.	1.9	9
268	A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development. Cytometry Part B - Clinical Cytometry, 2016, 90, 220-229.	0.7	8
269	Whatever happened to the Norwegian Medical Need Clause? Lessons for current debates in <scp>EU</scp> pharmaceutical regulation. Sociology of Health and Illness, 2016, 38, 576-591.	1.1	3
271	Identification of 1<i>H</i>â€‘indeneâ€‘(1,3,5,6)â€‘tetrol derivatives as potent pancreatic lipase inhibitors using molecular docking and molecular dynamics approach. Biotechnology and Applied Biochemistry, 2016, 63, 765-778.	1.4	8
272	3D Cancer Models on Hydrogels. , 2016, , 207-256.		1
273	Putting translational science on to a global stage. Nature Reviews Drug Discovery, 2016, 15, 217-218.	21.5	21
274	A complex game of hide and seek: the search for new antifungals. MedChemComm, 2016, 7, 1285-1306.	3.5	50
275	The evolution of drug discovery: from phenotypes to targets, and back. MedChemComm, 2016, 7, 788-798.	3.5	31
276	Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?. Clinical Cancer Research, 2016, 22, 2127-2132.	3.2	21
277	The analysis of the market success of FDA approvals by probing top 100 bestselling drugs. Journal of Computer-Aided Molecular Design, 2016, 30, 381-389.	1.3	10
278	Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. JACC Basic To Translational Science, 2016, 1, 301-308.	1.9	24
279	Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System. Drug Metabolism and Disposition, 2016, 44, 1731-1735.	1.7	42
280	Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid. Journal of Pharmaceutical Sciences, 2016, 105, 3243-3255.	1.6	23
281	The promises of quantitative systems pharmacology modelling for drugÂdevelopment. Computational and Structural Biotechnology Journal, 2016, 14, 363-370.	1.9	77

#	ARTICLE	IF	CITATIONS
282	Patents as a Spur to Subsequent Innovation? Evidence from Pharmaceuticals. American Economic Journal: Applied Economics, 2016, 8, 189-221.	1.5	10
283	Late-stage pharmaceutical R&D and pricing policies under two-stage regulation. Journal of Health Economics, 2016, 50, 298-311.	1.3	15
284	The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system. Expert Opinion on Drug Discovery, 2016, 11, 939-956.	2.5	10
285	Multidimensional complexity of cancer. Simple solutions are needed. Biochemistry (Moscow), 2016, 81, 731-738.	0.7	11
286	Fundamentally low reproducibility in molecular genetic cancer research. Russian Journal of Genetics, 2016, 52, 650-663.	0.2	5
287	Discovery of Novel Antischistosomal Agents by Molecular Modeling Approaches. Trends in Parasitology, 2016, 32, 874-886.	1.5	45
288	Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry. SpringerPlus, 2016, 5, 692.	1.2	29
292	Quality guidelines for oral drug candidates: dose, solubility and lipophilicity. Drug Discovery Today, 2016, 21, 1719-1727.	3.2	83
293	Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing. Scientific Reports, 2016, 6, 32745.	1.6	41
294	Non-Specificity of Drug-Target Interactions â€" Consequences for Drug Discovery. ACS Symposium Series, 2016, , 91-142.	0.5	2
295	Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files. Molecular Diversity, 2016, 20, 789-803.	2.1	6
297	Pharmacogenomic approaches to lipid-regulating trials. Current Opinion in Lipidology, 2016, 27, 557-562.	1.2	4
298	Future Directions in the Treatment of Gastrointestinal and Pancreatic Neuroendocrine Tumors. Pancreas, 2016, 45, 786-788.	0.5	1
299	<i>In silico</i> methods for drug repurposing and pharmacology. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2016, 8, 186-210.	6.6	250
300	Changing R&D models in research-based pharmaceutical companies. Journal of Translational Medicine, 2016, 14, 105.	1.8	231
301	Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia. Journal of Psychopharmacology, 2016, 30, 826-830.	2.0	26
302	Use of big data in drug development for precision medicine. Expert Review of Precision Medicine and Drug Development, 2016, 1, 245-253.	0.4	28
303	Pharmacogenomics to Revive Drug Development in Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2016, 30, 59-64.	1.3	7

#	ARTICLE	IF	CITATIONS
304	Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. Journal of Lipid Research, 2016, 57, 109-119.	2.0	50
305	Materials Research for Manufacturing. Springer Series in Materials Science, 2016, , .	0.4	5
306	Learning from successes and failures in pharmaceutical R&D. Journal of Evolutionary Economics, 2016, 26, 271-290.	0.8	14
307	Corning Incorporated: Designing a New Future with Glass and Optics. Springer Series in Materials Science, 2016, , 1-38.	0.4	3
308	Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Research, 2016, 44, D1069-D1074.	6.5	278
309	Drug self-assembly: A phenomenon at the nanometer scale with major impact in the structureâ€"biological properties relationship and the treatment of disease. Progress in Materials Science, 2016, 82, 39-82.	16.0	24
310	Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets. Drug Resistance Updates, 2016, 26, 10-27.	6.5	30
311	Compound annotation with real time cellular activity profiles to improve drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 269-280.	2.5	3
312	Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 2016, 47, 20-33.	1.3	2,229
313	Stimulated Raman scattering microscopy: an emerging tool for drug discovery. Chemical Society Reviews, 2016, 45, 2075-2089.	18.7	198
314	Targeting proteinâ€"protein interactions, a wide open field for drug design. Comptes Rendus Chimie, 2016, 19, 19-27.	0.2	96
315	Keeping it small, polar, and non-flat: diversely functionalized building blocks containing the privileged 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]- and [1,5-a]pyridine cores. Tetrahedron Letters, 2016, 57, 1056-1059.	0.7	7
316	Drug discovery in ophthalmology: past success, present challenges, and future opportunities. BMC Ophthalmology, 2016, 16, 11.	0.6	34
317	A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine. Journal of Biomolecular Screening, 2016, 21, 521-534.	2.6	46
318	Target Identification of Compounds from a Cell Viability Phenotypic Screen Using a Bead/Lysate-Based Affinity Capture Platform. Journal of Biomolecular Screening, 2016, 21, 201-211.	2.6	16
319	Human health benefits and burdens of a pharmaceutical treatment: Discussion of a conceptual integrated approach. Environmental Research, 2016, 144, 19-31.	3.7	14
320	Microfluidics for cell-based high throughput screening platformsâ€"A review. Analytica Chimica Acta, 2016, 903, 36-50.	2.6	216
321	Direct and mediated ties to universities: â€œScientificâ€•absorptive capacity and innovation performance of pharmaceutical firms. Strategic Organization, 2016, 14, 32-52.	3.1	58

#	Article	IF	Citations
322	Coordinating Knowledge Creation in Multidisciplinary Teams: Evidence from Early-Stage Drug Discovery. Academy of Management Journal, 2016, 59, 1308-1338.	4.3	92
323	The Dynamics of Pharmaceutical Regulation and R&D Investments. Journal of Public Economic Theory, 2017, 19, 121-141.	0.6	11
324	Antibiotic discovery throughout the Small World Initiative: A molecular strategy to identify biosynthetic gene clusters involved in antagonistic activity. MicrobiologyOpen, 2017, 6, e00435.	1.2	52
325	Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland. Value in Health, 2017, 20, 320-328.	0.1	53
326	Biofocussed chemoprospecting: An efficient approach for drug discovery. Chemical Biology and Drug Design, 2017, 90, 128-140.	1.5	2
327	Integrated, High-Throughput, Multiomics Platform Enables Data-Driven Construction of Cellular Responses and Reveals Global Drug Mechanisms of Action. Journal of Proteome Research, 2017, 16, 1364-1375.	1.8	34
328	Vaccines: Shaping global health. Vaccine, 2017, 35, 1579-1585.	1.7	6
329	Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation. AAPS Journal, 2017, 19, 607-618.	2.2	6
330	<i>In Vitro</i> Evaluation of the Ophthalmic Toxicity Profile of Chlorhexidine and Propamidine Isethionate Eye Drops. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 202-209.	0.6	14
331	Acquisitions in the biopharmaceutical <scp>IPO</scp> market: Collaboration, competition and coâ€‘opetition. Managerial and Decision Economics, 2017, 38, 1162-1171.	1.3	2
332	How excluding some benefits from value assessment of new drugs impacts innovation. Health Economics (United Kingdom), 2017, 26, 1813-1825.	0.8	3
333	Outlook for the Future. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 421-447.	0.2	0
334	Intraâ€‘Target Microdosing (ITM): A Novel Drug Development Approach Aimed at Enabling Safer and Earlier Translation of Biological Insights Into Human Testing. Clinical and Translational Science, 2017, 10, 337-350.	1.5	8
335	An engineering design approach to systems biology. Integrative Biology (United Kingdom), 2017, 9, 574-583.	0.6	22
337	Knowledge Development Approaches and Breakthrough Innovations in Technologyâ€‘Based New Firms. Journal of Product Innovation Management, 2017, 34, 492-508.	5.2	35
338	Hot-Spotting with Thermal Scanning: A Ligand- and Structure-Independent Assessment of Target Ligandability. Journal of Medicinal Chemistry, 2017, 60, 4923-4931.	2.9	18
339	Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS Discovery, 2017, 22, 456-472.	1.4	617
340	Methodological Rigor in Preclinical Cardiovascular Studies. Circulation Research, 2017, 120, 1916-1926.	2.0	118

#	Article	IF	Citations
341	Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS Discovery, 0, , 247255521769679.	1.4	10
342	Analysis of FDA-approved imaging agents. Drug Discovery Today, 2017, 22, 1077-1083.	3.2	12
343	Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2017, 60, 957-971.	2.9	47
344	Predicting new drug indications from network analysis. International Journal of Modern Physics C, 2017, 28, 1750118.	0.8	2
345	Ligand efficiency metrics in drug discovery: the pros and cons from a practical perspective. Expert Opinion on Drug Discovery, 2017, 12, 1087-1104.	2.5	75
346	The potential role of <i>in silico</i> approaches to identify novel bioactive molecules from natural resources. Future Medicinal Chemistry, 2017, 9, 1665-1686.	1.1	27
347	PhID: An Open-Access Integrated Pharmacology Interactions Database for Drugs, Targets, Diseases, Genes, Side-Effects, and Pathways. Journal of Chemical Information and Modeling, 2017, 57, 2395-2400.	2.5	9
348	Internationalization Effects in a Global Knowledge-Based Industry: A Study of Multinational Pharmaceutical Companies. , 2017, , 87-124.		1
349	â€œHaving a Structuring Effect on Europeâ€• The Innovative Medicines Initiative and the Construction of the European Health Bioeconomy. , 2017, , 73-101.		10
350	Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential. Scientific Reports, 2017, 7, 11261.	1.6	27
351	Dual targeting of the cancer antioxidant network with 1,4-naphthoquinone fused Gold(<scp>i</scp>) N-heterocyclic carbene complexes. Chemical Science, 2017, 8, 5918-5929.	3.7	60
352	Intraâ€Target Microdosing â€" A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans. Clinical and Translational Science, 2017, 10, 351-359.	1.5	6
353	The Burden of the â€œFalseâ€Negativesâ€•in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures. Clinical and Translational Science, 2017, 10, 470-479.	1.5	19
356	Strengthening the Cost Effectiveness of Medical Countermeasure Development Against Rare Biological Threats: The Ebola Outbreak. Pharmaceutical Medicine, 2017, 31, 423-436.	1.0	1
357	Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. Journal of Market Access & Health Policy, 2017, 5, 1298190.	0.8	13
358	Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine. JACC Basic To Translational Science, 2017, 2, 311-327.	1.9	61
359	Longitudinal assessment of bleomycin-induced lung fibrosis by Micro-CT correlates with histological evaluation in mice. Multidisciplinary Respiratory Medicine, 2017, 12, 8.	0.6	72
360	Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?. Journal of Autoimmunity, 2017, 85, 6-19.	3.0	11

#	Article	IF	Citations
361	Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. Cancer Treatment Reviews, 2017, 52, 12-21.	3.4	87
362	Coumestrol Inhibits Proliferation and Migration of Prostate Cancer Cells by Regulating AKT, ERK1/2, and JNK MAPK Cell Signaling Cascades. Journal of Cellular Physiology, 2017, 232, 862-871.	2.0	48
363	Putting the Patient Back Together â€" Social Medicine, Network Medicine, and the Limits of Reductionism. New England Journal of Medicine, 2017, 377, 2493-2499.	13.9	132
364	Venom based neural modulators (review). Experimental and Therapeutic Medicine, 2017, 15, 615-619.	0.8	0
365	Hybrid Compounds as Anti-infective Agents. Current Topics in Medicinal Chemistry, 2017, 17, 1080-1095.	1.0	11
366	Label-Free Screening Technologies. , 2017, , 416-433.		1
367	Discovery of AZD0156: The First Potent and Selective Inhibitor of ATM Kinase for Clinical Evaluation. , 2017, , 161-177.		4
368	Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations. International Journal of Molecular Sciences, 2017, 18, 448.	1.8	15
369	Adaptation through Collaboration: Developing Novel Platforms to Advance the Delivery of Advanced Therapies to Patients. Frontiers in Medicine, 2017, 4, 56.	1.2	12
371	Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS ONE, 2017, 12, e0181885.	1.1	16
372	Prediction of drug cocktail effects when the number of measurements is limited. PLoS Biology, 2017, 15, e2002518.	2.6	32
373	Bioprospecting saline gradient of a Wildlife Sanctuary for bacterial diversity and antimicrobial activities. BMC Research Notes, 2017, 10, 397.	0.6	3
374	Human PK Prediction and Modeling. , 2017, , 51-82.		1
375	Timely, Cheap, or Risk Free? The Effect of Regulation on the Price and the Availability of New Drugs. SSRN Electronic Journal, 0, , .	0.4	0
376	Fragment-Based Drug Design: Strategic Advances and Lessons Learned. , 2017, , 212-232.		9
377	Endogenous Productivity of Demand-Induced R&D: Evidence from Pharmaceuticals. SSRN Electronic Journal, 2017, , .	0.4	0
378	US Pharma's Financialized Business Model. SSRN Electronic Journal, 0, , .	0.4	44
379	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. , 2017, , 64-93.		0

#	Article	IF	Citations
380	One Lab, Two Firms, Many Possibilities: On R&D Outsourcing in the Biopharmaceutical Industry. SSRN Electronic Journal, 0, , .	0.4	3
381	Predicting Target and Chemical Druggability. , 2017, , 429-439.		2
382	Human Stakeholders and the Use of Animals in Drug Development. Business and Society Review, 2018, 123, 3-58.	0.9	11
384	Meta-QSAR: a large-scale application of meta-learning to drug design and discovery. Machine Learning, 2018, 107, 285-311.	3.4	55
385	Ligandomics: a paradigm shift in biological drug discovery. Drug Discovery Today, 2018, 23, 636-643.	3.2	15
386	Advances in Polymer Design for Enhancing Oral Drug Solubility and Delivery. Bioconjugate Chemistry, 2018, 29, 939-952.	1.8	97
387	The importance of greater speed in drug development for advanced malignancies. Cancer Medicine, 2018, 7, 1824-1836.	1.3	23
388	Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 1579-1593.	1.3	21
389	Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. Circulation Research, 2018, 122, 1021-1032.	2.0	111
390	The financial performance of the health care industry: a global, regional and industry specific empirical investigation. European Journal of Health Economics, 2018, 19, 585-594.	1.4	1
391	Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nature Reviews Drug Discovery, 2018, 17, 19-33.	21.5	106
392	Mathematical modeling of efficacy and safety for anticancer drugs clinical development. Expert Opinion on Drug Discovery, 2018, 13, 5-21.	2.5	7
393	Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands. Technological Forecasting and Social Change, 2018, 128, 133-143.	6.2	23
394	Biomaterialsâ€Based Approaches to Tumor Spheroid and Organoid Modeling. Advanced Healthcare Materials, 2018, 7, e1700980.	3.9	96
395	Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nature Reviews Drug Discovery, 2018, 17, 280-299.	21.5	247
396	The pharmaceutical market and drug development prognosis in Japan: Current and future perspectives according to pharmacological classes. Journal of Generic Medicines, 2018, 14, 70-80.	0.0	6
397	A multi-throughput multi-organ-on-a-chip system on a plate formatted pneumatic pressure-driven medium circulation platform. Lab on A Chip, 2018, 18, 115-125.	3.1	119
398	Publicâ€"private collaborations in drug development: boosting innovation or alleviating risk?. Public Management Review, 2018, 20, 273-292.	3.4	11

#	ARTICLE	IF	CITATIONS
399	Systemic Competitiveness Factors in the Pharma Industry's Productivity and Innovation in Mexico. , 2018, , .		0
400	Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry. International Journal of Political Economy, 2018, 47, 281-316.	0.3	48
402	Is the Pace of Biomedical Innovation Slowing?. Perspectives in Biology and Medicine, 2018, 61, 584-593.	0.3	5
403	Systems Biology: A Powerful Tool for Drug Development. Current Topics in Medicinal Chemistry, 2018, 18, 1745-1754.	1.0	9
404	Net Present Value-Based Analyses of Products in Development by Pharmaceutical and Biotech Firms: NPV-Based Analyses of Biopharmaceutical Products. , 2018, , .		1
405	Emerging Concepts and Techniques. , 2018, , 729-743.		0
406	Strategic decision-making in the pharmaceutical industry: A unified decision-making framework. Computers and Chemical Engineering, 2018, 119, 171-189.	2.0	12
407	Designing stem cell niches for differentiation and self-renewal. Journal of the Royal Society Interface, 2018, 15, 20180388.	1.5	107
408	Orphan Drugs and Their Impact on Pharmaceutical Development. Trends in Pharmacological Sciences, 2018, 39, 525-535.	4.0	43
409	SeaBioTech: From Seabed to Test-Bed: Harvesting the Potential of Marine Biodiversity for Industrial Biotechnology. Grand Challenges in Biology and Biotechnology, 2018, , 451-504.	2.4	4
410	R&D Success in Pharmaceutical Markets: A Duration Model Approach. Contributions To Economic Analysis, 2018, , 201-233.	0.1	2
413	Sex, drugs, and heart failure: a sexâ€sensitive review of the evidence base behind current heart failure clinical guidelines. ESC Heart Failure, 2018, 5, 745-754.	1.4	36
414	Filling the drug discovery gap: is high-content screening the missing link?. Current Opinion in Pharmacology, 2018, 42, 40-45.	1.7	21
415	Four Stages of Pharmaceutical Product Development. , 2018, , 637-668.		4
416	Preformulation in Drug Research and Pharmaceutical Product Development. , 2018, , 1-55.		4
417	Development of an Experimental Model for Analyzing Drug Resistance in Colorectal Cancer. Cancers, 2018, 10, 164.	1.7	26
418	Long-Term Collaboration Network Based on ClinicalTrials.gov Database in the Pharmaceutical Industry. Sustainability, 2018, 10, 322.	1.6	5
419	How to Achieve Better Results Using PASS-Based Virtual Screening: Case Study for Kinase Inhibitors. Frontiers in Chemistry, 2018, 6, 133.	1.8	27

#	Article	IF	Citations
420	SPIDR: small-molecule peptide-influenced drug repurposing. BMC Bioinformatics, 2018, 19, 138.	1.2	12
421	Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity. International Journal of Neuropsychopharmacology, 2018, 21, 962-977.	1.0	102
422	Stem cell bioengineering: building from stem cell biology. Nature Reviews Genetics, 2018, 19, 595-614.	7.7	76
423	Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005. BMJ: British Medical Journal, 2018, 361, k2130.	2.4	83
424	Mechanisms and Drug Development in Atrial Fibrillation. Pharmacological Reviews, 2018, 70, 505-525.	7.1	67
425	Structural changes and growth regimes. Journal of Evolutionary Economics, 2019, 29, 119-176.	0.8	21
426	IDENTIFYING FACTORS INFLUENCING THE PRICE OF TECHNOLOGY LICENSES: A FRAMEWORK GROUNDED IN NEGOTIATION RESEARCH. International Journal of Innovation Management, 2019, 23, 1950039.	0.7	1
427	Drug Repositioning for Schizophrenia and Depression/Anxiety Disorders: A Machine Learning Approach Leveraging Expression Data. IEEE Journal of Biomedical and Health Informatics, 2019, 23, 1304-1315.	3.9	60
428	Innovation Beyond Technology. Creative Economy, 2019, , .	0.1	14
429	Sirius: A Resource for Analyzing Drug-Disease Relationships for Drug Repositioning. Lecture Notes in Electrical Engineering, 2019, , 235-244.	0.3	0
430	Endogenous productivity of demand€induced R&D: evidence from pharmaceuticals. RAND Journal of Economics, 2019, 50, 591-614.	1.3	6
431	Translational Medicine Strategies in Alzheimer's Disease Drug Development. Handbook of Behavioral Neuroscience, 2019, , 349-362.	0.7	0
432	Business Model Design for Latecomers in Biopharmaceutical Industry: The Case of Korean Firms. Sustainability, 2019, 11, 4881.	1.6	1
433	Pharmaceutical crisis. , 2019, , 1-10.		0
434	The Art of War in Drug Development. JACC Basic To Translational Science, 2019, 4, 715-716.	1.9	1
435	Optimization of Protein€"Protein Interaction Measurements for Drug Discovery Using AFM Force Spectroscopy. IEEE Nanotechnology Magazine, 2019, 18, 509-517.	1.1	4
436	Heart Rate Variability as a Translational Biomarker for Emotional and Cognitive Deficits. Handbook of Behavioral Neuroscience, 2019, , 199-212.	0.7	4
437	Engineering microsystems to recapitulate brain physiology on a chip. Drug Discovery Today, 2019, 24, 1725-1730.	3.2	14

#	Article	IF	Citations
438	Switching from Batch to Continuous Reactors Is a Trajectory Optimization Problem. Industrial & Engineering Chemistry Research, 2019, 58, 13718-13736.	1.8	22
439	BiRWDDA: A Novel Drug Repositioning Method Based on Multisimilarity Fusion. Journal of Computational Biology, 2019, 26, 1230-1242.	0.8	14
440	Drug repositioning of herbal compounds via a machine-learning approach. BMC Bioinformatics, 2019, 20, 247.	1.2	37
441	Response of safety pharmacologists to challenges arising from the rapidly evolving changes in the pharmaceutical industry. Journal of Pharmacological and Toxicological Methods, 2019, 98, 106593.	0.3	4
442	The Potential for microRNA Therapeutics and Clinical Research. Frontiers in Genetics, 2019, 10, 478.	1.1	562
443	Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?. Journal of Medicinal Chemistry, 2019, 62, 10026-10043.	2.9	52
444	The private returns to knowledge: A comparison of ICT, biotechnologies, nanotechnologies, and green technologies. Technological Forecasting and Social Change, 2019, 145, 62-81.	6.2	18
445	An Overview of Genomic Biomarker Use in Cardiovascular Disease Clinical Trials. Clinical Pharmacology and Therapeutics, 2019, 106, 841-846.	2.3	3
446	Screening drugs for myocardial disease in vivo with zebrafish: an expert update. Expert Opinion on Drug Discovery, 2019, 14, 343-353.	2.5	13
447	Analysis of energy-related CO2 emissions in China's pharmaceutical industry and its driving forces. Journal of Cleaner Production, 2019, 223, 94-108.	4.6	42
448	Computational Drug Repurposing for Neurodegenerative Diseases. , 2019, , 85-118.		6
449	In Silico Repurposing of Cell Cycle Modulators for Cancer Treatment. , 2019, , 255-279.		0
450	Establishment and Analysis of a 3D Co-Culture Spheroid Model of Pancreatic Adenocarcinoma for Application in Drug Discovery. Methods in Molecular Biology, 2019, 1953, 163-179.	0.4	9
451	Encircling the regions of the pharmacogenomic landscape that determine drug response. Genome Medicine, 2019, 11, 17.	3.6	14
452	One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry. Journal of Health Economics, 2019, 65, 260-283.	1.3	8
453	Improving the odds of drug development success through human genomics: modelling study. Scientific Reports, 2019, 9, 18911.	1.6	112
454	Lost in translation: the valley of death across preclinical and clinical divide â€" identification of problems and overcoming obstacles. Translational Medicine Communications, 2019, 4, .	0.5	299
455	The Productivity of Drug Development: A Systematic Review. , 2019, , .		1

#	Article	IF	Citations
456	Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs. Journal of Medicinal Chemistry, 2019, 62, 1701-1714.	2.9	286
457	Does global drug innovation correspond to burden of disease? The neglected diseases in developed and developing countries. Health Economics (United Kingdom), 2019, 28, 123-143.	0.8	24
458	Using human experience to identify drug repurposing opportunities: theory and practice. British Journal of Clinical Pharmacology, 2019, 85, 680-689.	1.1	13
459	A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. The Lancet Gastroenterology and Hepatology, 2019, 4, 63-70.	3.7	15
460	Implementation of a Pipeline Using Disease-Disease Associations for Computational Drug Repurposing. Methods in Molecular Biology, 2019, 1903, 129-148.	0.4	4
461	Development of Human Target Validation Classification that Predicts Future Clinical Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 255-261.	1.3	1
462	Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery, 2019, 18, 41-58.	21.5	2,689
463	Deriving and Assessing Strategic Priorities for Outsourcing Partner Selection in Pharmaceutical R&D: an Approach Using Analytic Hierarchy Process (AHP) Based on 34 Experts’ Responses From Korean Pharmaceutical Industry. Journal of Pharmaceutical Innovation, 2019, 14, 66-75.	1.1	11
464	Social capital and innovation in a life science cluster: the role of proximity and family involvement. Journal of Technology Transfer, 2020, 45, 205-227.	2.5	34
465	REX technologies for profiling and decoding the electrophile signaling axes mediated by Rosetta Stone proteins. Methods in Enzymology, 2020, 633, 203-230.	0.4	5
466	The relationship of industry structure to open innovation: cooperative value creation in pharmaceutical consortia. R and D Management, 2020, 50, 116-135.	3.0	25
467	Streamlining drug discovery assays for cardiovascular disease using zebrafish. Expert Opinion on Drug Discovery, 2020, 15, 27-37.	2.5	13
468	Research and development spending and technical efficiency: evidence from biotechnology and pharmaceutical sector. International Journal of Production Research, 2020, 58, 6170-6184.	4.9	11
469	Key indicators of phase transition for clinical trials through machine learning. Drug Discovery Today, 2020, 25, 414-421.	3.2	26
470	Decision-support challenges in the chemical-pharmaceutical industry: Findings and future research directions. Computers and Chemical Engineering, 2020, 134, 106672.	2.0	30
471	Characteristics of Ophthalmology Trials Registered in ClinicalTrials.gov, 2007-2018. American Journal of Ophthalmology, 2020, 211, 132-141.	1.7	26
472	A design-thinking approach to therapeutic translation: tympanic regeneration. Current Opinion in Otolaryngology and Head and Neck Surgery, 2020, 28, 274-280.	0.8	1
473	Innovation in pharmaceutical R&D: mapping the research landscape. Scientometrics, 2020, 125, 1801-1832.	1.6	11

#	ARTICLE	IF	CITATIONS
474	Non-Parametric Analysis of Efficiency: An Application to the Pharmaceutical Industry. Mathematics, 2020, 8, 1522.	1.1	5
475	Stem cells in natural product and medicinal plant drug discoveryâ€"An overview of new screening approaches. Biomedicine and Pharmacotherapy, 2020, 131, 110730.	2.5	9
476	Is corporate R&D simply a matter of money? The combined effect of a firmâ€™s economic characteristics and its perception of science. Industry and Innovation, 2021, 28, 955-989.	1.7	2
477	Fabrication of Hollow Structures in Photodegradable Hydrogels Using a Multi-Photon Excitation Process for Blood Vessel Tissue Engineering. Micromachines, 2020, 11, 679.	1.4	6
478	Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies. Sustainability, 2020, 12, 5358.	1.6	10
479	How companies respond to growing research costs: cost control or value creation. International Journal of Technology Management, 2020, 82, 1.	0.2	5
480	Drug Repurposing Approaches to Combating Viral Infections. Journal of Clinical Medicine, 2020, 9, 3777.	1.0	23
481	Reprogramming of antibiotics to combat antimicrobial resistance. Archiv Der Pharmazie, 2020, 353, e2000168.	2.1	15
482	Strategic Patenting by Pharmaceutical Companies â€" Should Competition Law Intervene?. IIC International Review of Intellectual Property and Competition Law, 2020, 51, 1062-1085.	0.3	19
483	Quantification of clinically applicable stimulation parameters for precision near-organ neuromodulation of human splenic nerves. Communications Biology, 2020, 3, 577.	2.0	14
484	In silico assessment of natural products and approved drugs as potential inhibitory scaffolds targeting aminoacyl-tRNA synthetases from Plasmodium. 3 Biotech, 2020, 10, 470.	1.1	1
485	A co-citation study of information security patents in the USPTO database. Library Hi Tech, 2021, 39, 936-950.	3.7	6
486	The New Normal in Clinical Trials: Decentralized Studies. Annals of Neurology, 2020, 88, 863-866.	2.8	45
487	Uncovering New Drug Properties in Target-Based Drugâ€"Drug Similarity Networks. Pharmaceutics, 2020, 12, 879.	2.0	14
488	Phase 0/microdosing approaches: time for mainstream application in drug development?. Nature Reviews Drug Discovery, 2020, 19, 801-818.	21.5	55
489	A New Computational Approach to Evaluating Systemic Geneâ€"Gene Interactions in a Pathway Affected by Drug LY294002. Processes, 2020, 8, 1230.	1.3	2
490	Are Ideas Getting Harder to Find?. American Economic Review, 2020, 110, 1104-1144.	4.0	330
491	Evolving Outsourcing Landscape in Pharma R&D: Different Collaborative Models and Factors To Consider When Choosing a Contract Research Organization. Journal of Medicinal Chemistry, 2020, 63, 11362-11367.	2.9	13

#	ARTICLE	IF	CITATIONS
492	Identifying drugs with disease—modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2020, 29, 864-872.	0.9	22
495	Empirical Regularities. , 2020, , 9-22.		0
496	Innovation and the Growth of Business Firms A Stochastic Framework. , 2020, , 23-92.		0
497	Testing Our Predictions. , 2020, , 93-123.		0
498	Testing Our Assumptions. , 2020, , 124-153.		0
503	Machine Learning Algorithm Identifies an Antibiotic Vocabulary for Permeating Gram-Negative Bacteria. Journal of Chemical Information and Modeling, 2020, 60, 2838-2847.	2.5	21
504	The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. , 2020, 213, 107579.		62
505	A systematic strategy for the investigation of vaccines and drugs targeting bacteria. Computational and Structural Biotechnology Journal, 2020, 18, 1525-1538.	1.9	13
506	Resource interdependence and project termination: An analysis in the biopharmaceutical industry. International Journal of Project Management, 2020, 38, 256-266.	2.7	7
507	A novel drug repurposing approach for non-small cell lung cancer using deep learning. PLoS ONE, 2020, 15, e0233112.	1.1	23
508	A comprehensive map of disease networks and molecular drug discoveries for glaucoma. Scientific Reports, 2020, 10, 9719.	1.6	3
509	Intensive care for human hearts in pluripotent stem cell models. Npj Regenerative Medicine, 2020, 5, 4.	2.5	6
510	Emerging applications of paper-based analytical devices for drug analysis: A review. Analytica Chimica Acta, 2020, 1116, 70-90.	2.6	113
511	Drug targets for COVID-19 therapeutics: Ongoing global efforts. Journal of Biosciences, 2020, 45, 1.	0.5	69
512	Moderating Effect of the Continental Factor on the Business Strategy and M&A Performance in the Pharmaceutical Industry for Sustainable International Business. Sustainability, 2020, 12, 4985.	1.6	4
513	Exploring different approaches to improve the success of drug discovery and development projects: a review. Future Journal of Pharmaceutical Sciences, 2020, 6, .	1.1	81
514	Drug repurposing: Discovery of troxipide analogs as potent antitumor agents. European Journal of Medicinal Chemistry, 2020, 202, 112471.	2.6	11
515	Biomolecular display technology: a new tool for drug discovery. , 2020, , 423-440.		0

#	ARTICLE	IF	CITATIONS
516	Innovation efficiency in European high-tech industries: Evidence from a Bayesian stochastic frontier approach. Research Policy, 2020, 49, 104054.	3.3	31
517	Target identification among known drugs by deep learning from heterogeneous networks. Chemical Science, 2020, 11, 1775-1797.	3.7	193
518	Expanding Tiny Earth to genomics: a bioinformatics approach for an undergraduate class to characterize antagonistic strains. FEMS Microbiology Letters, 2020, 367, .	0.7	16
519	Domain-adversarial multi-task framework for novel therapeutic property prediction of compounds. Bioinformatics, 2020, 36, 2848-2855.	1.8	8
520	Executable cancer models: successes and challenges. Nature Reviews Cancer, 2020, 20, 343-354.	12.8	43
521	The endless frontier? The recent increase of R&D productivity in pharmaceuticals. Journal of Translational Medicine, 2020, 18, 162.	1.8	42
522	Rushed Innovation: Evidence from Drug Licensing. Management Science, 2021, 67, 257-278.	2.4	13
523	Association Mining to Identify Microbe Drug Interactions Based on Heterogeneous Network Embedding Representation. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 266-275.	3.9	23
524	Structure-based drug repositioning: Potential and limits. Seminars in Cancer Biology, 2021, 68, 192-198.	4.3	26
525	Current development of integrated web servers for preclinical safety and pharmacokinetics assessments in drug development. Briefings in Bioinformatics, 2021, 22, .	3.2	12
526	Artificial intelligence and innovation management: A review, framework, and research agendaâœ°. Technological Forecasting and Social Change, 2021, 162, 120392.	6.2	224
527	Learning and dropout in contests: an experimental approach. Theory and Decision, 2021, 90, 245-278.	0.5	4
528	Time to Get Turned on by Chemical Biology. ChemBioChem, 2021, 22, 814-817.	1.3	3
529	Using artificial intelligence to identify antiâ€hypertensives as possible disease modifying agents in Parkinson's disease. Pharmacoepidemiology and Drug Safety, 2021, 30, 201-209.	0.9	11
530	Automation and data-driven design of polymer therapeutics. Advanced Drug Delivery Reviews, 2021, 171, 1-28.	6.6	46
531	Bridging the gap between invention and innovation: Increasing success rates in publicly and industry-funded clinical trials. Research Policy, 2021, 50, 104155.	3.3	7
532	Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets. Seminars in Cancer Biology, 2021, 68, 59-74.	4.3	64
533	Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis. Health Economics Review, 2021, 11, 4.	0.8	12

#	Article	IF	Citations
534	Approaches for the integration of big data in translational medicine: single‑cell and computational methods. Annals of the New York Academy of Sciences, 2021, 1493, 3-28.	1.8	8
535	Early Development of Erenumab for Migraine Prophylaxis. , 2021, , 245-255.		1
536	Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor. Computational and Structural Biotechnology Journal, 2021, 19, 3674-3681.	1.9	9
537	The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients. IEEE Transactions on Biomedical Engineering, 2022, 69, 412-421.	2.5	9
538	Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Research, 2021, 6, 16.	0.9	90
539	Individual Innovativeness, Motivational Persistence and Performance in Health. Mersin Ãœniversitesi TÄ±p FakÃ¼ltesi Lokman Hekim TÄ±p Tarihi Ve Folklorik TÄ±p Dergisi, 2021, 11, 10-15.	0.3	5
540	Monobodies as tool biologics for accelerating target validation and druggable site discovery. RSC Medicinal Chemistry, 2021, 12, 1839-1853.	1.7	10
541	Application of Network Pharmacology Based on Artificial Intelligence Algorithms in Drug Development. , 2021, , 35-73.		2
542	A Decade of FDA-Approved Drugs (2010â€"2019): Trends and Future Directions. Journal of Medicinal Chemistry, 2021, 64, 2312-2338.	2.9	145
543	Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery. Current Drug Research Reviews, 2021, 13, 101-119.	0.7	12
544	Exploring network dynamics in science: the formation of ties to knowledge translators in clinical research. Journal of Evolutionary Economics, 2021, 31, 1433-1464.	0.8	6
545	The role of patent expiration in acquisition decision and target selection in the pharmaceutical industry. R and D Management, 2021, 51, 521.	3.0	0
546	Clinico-Pathological Importance of miR-146a in Lung Cancer. Diagnostics, 2021, 11, 274.	1.3	19
547	Public subsidies for R&D and public sector pharmaceutical innovation. Applied Economics, 2021, 53, 3759-3777.	1.2	6
548	Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Research, 2021, 6, 16.	0.9	48
549	On the role of Brain Imaging in drug development for psychiatry. Current Clinical Pharmacology, 2021, 16, 46-71.	0.2	0
550	Utiliser la recherche pour soigner le cancerÂ: lâ€™innovation biomÃ©dicale localisÃ©e. Revue Francaise De Sociologie, 2021, Vol. 61, 405-433.	0.9	2
551	A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. 3 Biotech, 2021, 11, 198.	1.1	15

#	ARTICLE	IF	CITATIONS
553	A call to action for new global approaches to cardiovascular disease drug solutions. European Heart Journal, 2021, 42, 1464-1475.	1.0	29
555	Centrality analysis in a drug network and its application to drug repositioning. Applied Mathematics and Computation, 2021, 395, 125870.	1.4	4
556	Use of artificial intelligence to enhance phenotypic drug discovery. Drug Discovery Today, 2021, 26, 887-901.	3.2	30
557	Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Clinical and Translational Science, 2021, 14, 1113-1122.	1.5	35
558	Repurposing of Acriflavine to Target Chronic Myeloid Leukemia Treatment. Current Medicinal Chemistry, 2021, 28, 2218-2233.	1.2	19
559	The translational lag narrative in policy discourse in the United States and the European Union: a comparative study. Humanities and Social Sciences Communications, 2021, 8, .	1.3	6
560	The interplay between lipid and AÎ² amyloid homeostasis in Alzheimerâ€™s Disease: risk factors and therapeutic opportunities. Chemistry and Physics of Lipids, 2021, 236, 105072.	1.5	16
561	In vivo antidiabetic potential of standardized Gymnocarpos decandrus Forssk. Extract. Journal of Diabetes and Metabolic Disorders, 2021, 20, 1129-1135.	0.8	2
562	Pharmaceutical innovation and its crisis: drug markets, screening, and the dialectics of value. BioSocieties, 2021, 16, 411-432.	0.8	3
563	Academic collaborative models fostering the translation of physiological in vitro systems from basic research into drug discovery. Drug Discovery Today, 2021, 26, 1369-1381.	3.2	6
564	COVID-19, IP and access: Will the current system of medical innovation and access to medicines meet global expectations?. Journal of Generic Medicines, 2021, 17, 61-70.	0.0	4
565	Les fÃ©licitÃ©s du capital en santÃ©. Revue FranÃ§aise De Socio-Ã‰conomie, 2021, nÂ° 26, 127-147.	0.0	1
566	Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms. Pharmacological Research, 2021, 168, 105582.	3.1	65
567	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. Circulation, 2021, 144, 159-169.	1.6	18
568	Advancing the use of genome-wide association studies for drug repurposing. Nature Reviews Genetics, 2021, 22, 658-671.	7.7	102
569	Absorbing knowledge from an emerging field: The role of interfacing by proponents in big pharma. Technovation, 2022, 110, 102363.	4.2	3
570	R&D efficiency of leading pharmaceutical companies â€“ A 20-year analysis. Drug Discovery Today, 2021, 26, 1784-1789.	3.2	25
571	How the COVID-19 pandemic is changing clinical trial conduct and driving innovation in bioanalysis. Bioanalysis, 2021, 13, 1195-1203.	0.6	14

#	Article	IF	Citations
572	How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. Pharmacoeconomics, 2021, 39, 1243-1269.	1.7	94
573	Predicting drug approvals: The Novartis data science and artificial intelligence challenge. Patterns, 2021, 2, 100312.	3.1	17
574	Nitrofurazone repurposing towards design and synthesis of novel apoptotic-dependent anticancer and antimicrobial agents: Biological evaluation, kinetic studies and molecular modeling. Bioorganic Chemistry, 2021, 113, 104971.	2.0	4
575	A Personalized Glomerulus Chip Engineered from Stem Cell-Derived Epithelium and Vascular Endothelium. Micromachines, 2021, 12, 967.	1.4	31
576	Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19. Journal of Biomolecular Structure and Dynamics, 2022, 40, 11787-11808.	2.0	4
577	Targeting Reactive Oxygen Species Capacity of Tumor Cells with Repurposed Drug as an Anticancer Therapy. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-17.	1.9	13
578	Aminoquinolines as Translational Models for Drug Repurposing: Anticancer Adjuvant Properties and Toxicokinetic-Related Features. Journal of Oncology, 2021, 2021, 1-18.	0.6	6
579	Clinical connectivity map for drug repurposing: using laboratory results to bridge drugs and diseases. BMC Medical Informatics and Decision Making, 2021, 21, 263.	1.5	6
580	Effects of Naodesheng tablets on amyloid beta-induced dysfunction: A traditional Chinese herbal formula with novel therapeutic potential in Alzheimer's disease revealed by systems pharmacology. Biomedicine and Pharmacotherapy, 2021, 141, 111916.	2.5	5
581	Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing. Computers in Biology and Medicine, 2021, 138, 104856.	3.9	12
582	Discovery Formulations: Approaches and Practices in Early Preclinical Development. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 49-94.	0.2	8
583	Challenges and Opportunities in Enabling High-Throughput, Miniaturized High Content Screening. Methods in Molecular Biology, 2018, 1683, 165-191.	0.4	6
584	Computational Modeling of Multi-target-Directed Inhibitors Against Alzheimer's Disease. Neuromethods, 2018, , 533-571.	0.2	6
585	An Evolutionary Analysis of Health. Healthy Ageing and Longevity, 2020, , 13-34.	0.2	1
586	Inferring Drug-miRNA Associations by Integrating Drug SMILES and MiRNA Sequence Information. Lecture Notes in Computer Science, 2020, , 279-289.	1.0	2
587	Bridging a Pharma-Like Innovation Gap in Medical Nutrition. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 29-52.	0.2	2
589	Genetic Rat Models for Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 303-324.	0.7	4
591	Funding and Financing: Fresh Thinking Required. , 2016, , 115-148.		1

#	ARTICLE	IF	CITATIONS
595	An open toolkit for tracking open science partnership implementation and impact. Gates Open Research, 0, 3, 1442.	2.0	2
596	An open toolkit for tracking open science partnership implementation and impact. Gates Open Research, 2019, 3, 1442.	2.0	10
597	Resonant Waveguide Grating Biosensors for Cell Biology and Drug Discovery. , 2012, , .		3
598	Tracking 20 Years of Compound-to-Target Output from Literature and Patents. PLoS ONE, 2013, 8, e77142.	1.1	17
599	Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning. PLoS ONE, 2014, 9, e87864.	1.1	90
600	When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis. PLoS ONE, 2016, 11, e0147215.	1.1	202
602	In silico clinical trials: how computer simulation will transform the biomedical industry. International Journal of Clinical Trials, 2016, 3, 37.	0.0	155
603	Low-dose salinomycin induces anti-leukemic responses in AML and MLL. Oncotarget, 2016, 7, 73448-73461.	0.8	11
604	Structural Changes and Growth Regimes. SSRN Electronic Journal, 0, , .	0.4	3
605	Is Market Orientation a Driver for 'Radical Innovation'? An Insight from the Pharmaceutical Industry. SSRN Electronic Journal, 0, , .	0.4	1
606	Hierarchy of Knowledge Translation: From Health Problems to Ad-Hoc Drug Design. Current Medicinal Chemistry, 2016, 23, 3000-3012.	1.2	2
607	The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization. Current Medicinal Chemistry, 2019, 26, 3838-3873.	1.2	47
608	Recent Advances in Drug Repurposing for Parkinson's Disease. Current Medicinal Chemistry, 2019, 26, 5340-5362.	1.2	9
609	Applications of in Silico Methods for Design and Development of Drugs Targeting Protein-Protein Interactions. Current Topics in Medicinal Chemistry, 2019, 19, 534-554.	1.0	10
610	Patenting Networking and Knowledge Translation in Liposomes for Cancer Therapy. Recent Patents on Nanomedicine, 2015, 4, 121-128.	0.5	2
611	Repairing the 'Broken Middle' of the Health Innovation Pathway. Science and Technology Studies, 2013, 26, 103-123.	0.6	13
612	Using Inside-Out Open Innovation to Recover Abandoned Pharmaceutical Compounds. Journal of Innovation Management, 2015, 3, 21-32.	0.9	21
613	Government as the First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals 2010–2019. , 2020, , 1-72.		6

#	ARTICLE	IF	CITATIONS
614	Drug Discovery. Advances in Medical Technologies and Clinical Practice Book Series, 2019, , 1-46.	0.3	1
615	Innovation in the Era of Experience: The Changing Role of Users in Healthcare Innovation. Journal of Entrepreneurship, Management and Innovation, 2016, 12, 29-51.	0.6	3
616	The Context and the Problem. Munich Studies on Innovation and Competition, 2021, , 9-43.	0.1	0
619	Multi-Organs-on-Chips for Testing Small-Molecule Drugs: Challenges and Perspectives. Pharmaceutics, 2021, 13, 1657.	2.0	14
620	Human Genomics and Drug Development. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a039230.	2.9	16
621	Modelling Human Physiology on-Chip: Historical Perspectives and Future Directions. Micromachines, 2021, 12, 1250.	1.4	9
622	Emerging Concepts and Techniques. , 2010, , 731-741.		0
623	Servant Firms in Drug Discovery: a Neglected Project Based Organizational Form. SSRN Electronic Journal, 0, , .	0.4	2
625	A Look to the Environment and the Impact on OPEX. , 2013, , 77-102.		0
626	Opportunities and Challenges for Innovation in Pharmaceuticals: Now or Never!. Revista Virtual De Quimica, 2013, 5, .	0.1	1
627	Development of a New Approach to Systems Biology and Therapy Design. Series on Knots and Everything, 2014, , 347-369.	0.0	0
629	Drug Prices and Incentives to Innovation by the Pharmaceutical Industry. , 2015, , 389-401.		3
630	Wiederkehrend innovieren â€" sich selbst immer wieder neu erfinden. , 2015, , 15-38.		0
631	Can Innovation Still Be the Main Growth Driver of the Pharmaceutical Industry?. Perspectives on Sustainable Growth, 2015, , 39-68.	0.3	1
632	How Excluding Some Benefits from Value Assessment of New Medicines Impacts Innovation. SSRN Electronic Journal, 0, , .	0.4	0
633	Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value. SSRN Electronic Journal, 0, , .	0.4	1
634	Direct and Mediated Ties to Universities: Scientificc Absorptive Capacity and Innovation Performance of Pharmaceutical Firms. SSRN Electronic Journal, 0, , .	0.4	0
638	Brazilian Health Biotechnology Innovation System: an essay about the public policy rationale. Fronteiras, 2016, 5, 14.	0.0	1

#	ARTICLE	IF	CITATIONS
639	Construction of Enriched Resource for Primary Therapeutic Targets of Approved and Clinical Trial Drugs. Journal of Biosciences and Medicines, 2017, 05, 1-6.	0.1	0
640	Systems Chemical Biology: Integrating Medicinal Chemistry and Systems Biology for Drug Discovery. , 2017, , 481-494.		0
641	Case I: 3DMed: An R&D Platform for Personalised Precision Anti-cancer Drugs. Management for Professionals, 2018, , 1-32.	0.3	1
643	Technical Change and the Incorporation of Biotechnology in the Pharmaceutical Industry. , 0, , .		0
644	Targeted drug discovery and development, from molecular signaling to the global market: an educational program at New York University, 5-year metrics. Journal of Translational Science, 2018, 4, 1-9.	0.2	21
645	Le crowdfunding au secours de lâ€™industrie des biotechnologies santÃ©Â?. Revue Francaise De Gestion, 2018, 44, 135-157.	0.1	1
646	Pharmamarketing, Strafrecht, Selbstregulierung â€" EinfÃ¼hrung in den Band. , 2019, , 1-26.		0
647	4. Lâ€™institutionnalisation progressive des essais prÃ©coces en France. , 2019, , 81-98.		3
648	Target Identification Among Known Drugs by Deep Learning from Heterogeneous Networks. SSRN Electronic Journal, 0, , .	0.4	3
650	Rushed Innovation: Reactive Licensing in the Pharmaceutical Industry. SSRN Electronic Journal, 0, , .	0.4	0
651	High Drug Prices, Big R&D Spenders and 'Free Riders': Canada in the Topsy Turvy World of Pharmaceuticals. SSRN Electronic Journal, 0, , .	0.4	0
652	Drug Formulations. , 2020, , 57-88.		0
653	Illiquidity, R&D Investment, and Stock Returns. SSRN Electronic Journal, 0, , .	0.4	0
655	Limitations and Flaws of Preclinical Pulmonary Hypertension Studies. Advances in Pulmonary Hypertension, 2020, 19, 47-54.	0.1	0
656	Impact of public R&D as market matures: Evidence from solar PV industry. Energy and Environment, 2021, 32, 1543-1558.	2.7	0
657	Supporting secondary research in early drug discovery process through a Natural Language Processing based system. Proceedings of the International Conference on Applied Statistics, 2020, 2, 254-267.	0.1	1
658	Supporting secondary research in early drug discovery process through a Natural Language Processing based system. Proceedings of the International Conference on Applied Statistics, 2020, 2, 209-222.	0.1	0
659	Drug discovery. , 2022, , 563-572.		1

#	ARTICLE	IF	CITATIONS
660	New Medicines for Serious Diseases: The Case of the FDA's Breakthrough Designation. SSRN Electronic Journal, 0, , .	0.4	0
661	Institutional Corruption of Medical Knowledge Production. Studies of Organized Crime, 2020, , 115-144.	0.4	0
662	Artificial Intelligence and Drug Innovation: A Large Scale Examination of the Pharmaceutical Industry. SSRN Electronic Journal, 0, , .	0.4	3
663	R&D Productivity in the Pharmaceutical Industry. , 0, , 302-320.		0
664	SETTING THE "RIGHT" GOAL: POST M&A INNOVATION PERFORMANCE AND GOAL ORIENTATION. Business: Theory and Practice, 2020, 21, 555-565.	0.8	0
666	Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity. AMIA ... Annual Symposium proceedings, 2014, 2014, 1258-67.	0.2	34
667	Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biology and Medicine, 2015, 12, 316-27.	1.4	5
668	Adapt to Translate. European Journal of Analytic Philosophy, 2021, 17, 5-24.	0.8	3
669	Improving Translational Paradigms in Drug Discovery and Development. Current Protocols, 2021, 1, e273.	1.3	3
670	Innovation crisis in the pharmaceutical industry? A survey. SN Business & Economics, 2021, 1, 1.	0.6	11
672	Регулирование клинических исследований по правам...в.ёвропе		
673	Cost-effectiveness analysis of in silico clinical trials of vascular stents. , 2021, , .		0
674	Characterization of the Microflow Through 3D Synthetic Niche Microenvironments Hosted in a Millifluidic Bioreactor. Frontiers in Bioengineering and Biotechnology, 2021, 9, 799594.	2.0	0
675	DDA-SKF: Predicting Drug–Disease Associations Using Similarity Kernel Fusion. Frontiers in Pharmacology, 2021, 12, 784171.	1.6	6
676	Prediction of Drug Targets for Specific Diseases Leveraging Gene Perturbation Data: A Machine Learning Approach. Pharmaceutics, 2022, 14, 234.	2.0	6
677	Pharmaceutical spending and early-stage innovation in EU countries. Industry and Innovation, 2022, 29, 1141-1170.	1.7	2
678	Crowdsourcing research questions in science. Research Policy, 2022, 51, 104491.	3.3	17
679	Profitability and drug discovery. Industrial and Corporate Change, 2022, 31, 891-904.	1.7	4

#	ARTICLE	IF	CITATIONS
680	Evolution of Artificial Intelligence-Powered Technologies in Biomedical Research and Healthcare. Advances in Biochemical Engineering/Biotechnology, 2022, , 23-60.	0.6	9
681	Towards a general framework for innovation shaped with AI to create and transform market offerings. European Management Review, 0, , .	2.2	3
682	Recycled Translation: Repurposing Drugs for Stroke. Translational Stroke Research, 2022, 13, 866-880.	2.3	5
683	Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe. International Journal of Health Policy and Management, 2022, , .	0.5	5
684	Systemic Efficacy of Sirolimus via the ERBB Signaling Pathway in Breast Cancer. Processes, 2022, 10, 552.	1.3	1
685	In Vitro Cancer Models: A Closer Look at Limitations on Translation. Bioengineering, 2022, 9, 166.	1.6	11
686	Analysis of the anti-inflammatory potential of Brassica bioactive compounds in a human macrophage-like cell model derived from HL-60 cells. Biomedicine and Pharmacotherapy, 2022, 149, 112804.	2.5	10
687	Inhibition of PDK3 by artemisinin, a repurposed antimalarial drug in cancer therapy. Journal of Molecular Liquids, 2022, 355, 118928.	2.3	16
688	Multipurpose Drugs Active Against Both Plasmodium spp. and Microorganisms: Potential Application for New Drug Development. Frontiers in Cellular and Infection Microbiology, 2021, 11, 797509.	1.8	1
689	Drug Repurposing Using Modularity Clustering in Drug-Drug Similarity Networks Based on Drugâ€"Gene Interactions. Pharmaceutics, 2021, 13, 2117.	2.0	11
690	New therapeutic modalities in drug discovery and development: Insights & opportunities. ADMET and DMPK, 2021, 9, 227-230.	1.1	4
691	Inequities in cancer drug development in terms of unmet medical need. Social Science and Medicine, 2022, 302, 114953.	1.8	2
696	The changing world of oncology drug development-A global pharmaceutical company's perspective. Chinese Clinical Oncology, 2014, 3, 20.	0.4	6
698	Health technology assessment processes: a North-South comparison of the evaluation andÂrecommendation of health technologies in Canada and Chile. International Journal of Health Governance, 2022, 27, 312-328.	0.6	2
699	Investment choices and production dynamics: The role of price expectations, financial deficit, and production constraints. Journal of Economics and Business, 2022, 120, 106067.	1.7	1
700	Collaborative universityâ€"industry R&D practices supporting the pharmaceutical innovation process: Insights from a bibliometric review. Drug Discovery Today, 2022, 27, 2333-2341.	3.2	10
701	Economic analysis for in silico clinical trials of biodegradable and metallic vascular stents. , 2022, , 271-291.		0
703	Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers. International Journal of Transgender Health, 2022, 15, 568-601.	1.1	2

#	Article	IF	Citations
704	System and network biology-based computational approaches for drug repositioning. , 2022, , 267-290.		3
705	Innovation in Pharmaceutical Assistance. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	0
706	Endogeneity in pharmaceutical knowledge generation: An instrumentâ€free copula approach for Poisson frontier models. Journal of Economics and Management Strategy, 2022, 31, 942-960.	0.4	2
707	Liver-on-a-chip devices: the pros and cons of complexity. American Journal of Physiology - Renal Physiology, 2022, 323, G188-G204.	1.6	12
708	Three-Dimensional In Vitro Cell Culture Models for Efficient Drug Discovery: Progress So Far and Future Prospects. Pharmaceuticals, 2022, 15, 926.	1.7	26
709	Social Media Mining of Long-COVID Self-Medication Reported by Reddit Users: Feasibility Study to Support Drug Repurposing. JMIR Formative Research, 2022, 6, e39582.	0.7	4
710	Targeting the tamoxifen receptor within sodium channels to block osteoarthritic pain. Cell Reports, 2022, 40, 111248.	2.9	1
711	The Structureâ€"property Relationships of Clinically Approved Protein Kinase Inhibitors. Current Medicinal Chemistry, 2023, 30, 2518-2541.	1.2	1
713	Generic competition and the incentives for early-stage pharmaceutical innovation. Research Policy, 2022, 51, 104595.	3.3	2
714	General Strategies for Rational Design and Discovery of Multitarget Drugs. , 2022, , 677-736.		0
715	Predictive validity in drug discovery: what it is, why it matters and how to improve it. Nature Reviews Drug Discovery, 2022, 21, 915-931.	21.5	28
717	Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities. Frontiers in Pharmacology, 0, 13, .	1.6	6
718	Semantic Breakthrough in Drug Discovery. Synthesis Lectures on Data, Semantics and Knowledge, 2015, , .	3.9	2
719	Dâ€™une pandÃ©mie Ã lâ€™autre, raretÃ© artificielle et rente sous brevet de mÃ©dicament. Ã‰conomie Et Institutions, 2022, , .	0.1	0
720	Impact of Pharmaceutical R&D Activity on Financial Flexibility and Bargaining Power. Economies, 2022, 10, 277.	1.2	2
721	Cell morphology-guided <i>de novo</i> hit design by conditioning GANs on phenotypic image features. , 2023, 2, 91-102.		4
722	Optimizing drug discovery: An opportunity and application with reverse translational research. Health Sciences Review, 2023, 6, 100074.	0.6	0
723	Goals for DMPK During Drug Optimizations. , 2022, , 1-9.		0

#	ARTICLE	IF	CITATIONS
724	Hibernation or Transformation? Challenges in Cardiovascular Drug Development. Frontiers in Cardiovascular Drug Discovery, 2022, , 102-140.	0.0	0
725	A proof-of-concept study poised to remodel the drug development process. Frontiers in Medical Technology, 0, 4, .	1.3	2
726	Papers and patents are becoming less disruptive over time. Nature, 2023, 613, 138-144.	13.7	182
727	Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers. International Journal of Molecular Sciences, 2023, 24, 1334.	1.8	17
728	GNAEMDA: Microbe-Drug Associations Prediction on Graph Normalized Convolutional Network. IEEE Journal of Biomedical and Health Informatics, 2023, 27, 1635-1643.	3.9	3
729	Valuing Pharmaceutical Drug Innovations: An Event Study Approach. SSRN Electronic Journal, 0, , .	0.4	0
730	Strategies to Combat Multidrug Resistance by Non-traditional Therapeutic Approaches. , 2023, , 57-78.		0
731	Advances in synthetic biology of fungi and contributions to the discovery of new molecules. ChemBioChem, 0, , .	1.3	0
733	Patient engagement in drug development: configuring a new resource for generating innovation. Critical Public Health, 2023, 33, 506-517.	1.4	1
734	Illiquidity, R&D Investment, and Stock Returns. Journal of Money, Credit and Banking, 0, , .	0.9	1
737	Lead Optimisation: What You Should Know!. , 2023, , 720-768.		0
739	A MIST conception: what has been learned from twenty years of human metabolite safety assessment?. Medicinal Chemistry Research, 2023, 32, 1933-1949.	1.1	3
746	Systems biology and data science in research and translational medicine. , 2023, , 25-39.		0
747	Transitioning Up to Best Practice, or Down to the Bare Minimum? Global Harmonisation of Regulation of Therapeutic Goods. , 2023, , 45-65.		0
752	Phospholipases as therapeutic targets: Systems biology and bioinformatics approaches. , 2023, , 359-374.		0
758	Artificial Intelligence and Machine Learning in Drug Discovery and Development. Advances in Computational Intelligence and Robotics Book Series, 2023, , 42-61.	0.4	0
765	Challenges in Drug Development for Neurological Disorders. , 2023, , 27-45.		0
769	AI/ML and drug repurposing in lung cancer: State of the art and potential roles for retinoids. , 2024, , 47-61.		0